Equities

Tristel PLC

Tristel PLC

Actions
  • Price (EUR)5.10
  • Today's Change-0.10 / -1.92%
  • Shares traded100.00
  • 1 Year change+8.51%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 08:13 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tristel plc is a United Kingdom-based manufacturer of infection prevention products. The Company's core business is the sale to hospitals of its chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. The Company operates through three segments: Hospital medical device decontamination, Hospital environmental surface disinfection and others. It manufactures and sells medical device decontamination products which are used primarily for infection control in hospitals. The Company also manufactures and sells hospital environmental surface disinfection products. The Company is also focused on pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare sectors. The Tristel brand offers airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal (GI) physiology, laboratory, ophthalmology, and ultrasound.

  • Revenue in GBP (TTM)41.93m
  • Net income in GBP6.49m
  • Incorporated2003
  • Employees213.00
  • Location
    Tristel PLCLynx Business Park,Fordham RoadSNAILWELL CB8 7NYUnited KingdomGBR
  • Phone+44 163 872 1500
  • Fax+44 163 872 1911
  • Websitehttps://tristel.com/hk-en/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.